Boehringer Ingelheim USA Corporation

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Home-based Study Using Mobile Technology to Test Whether BI 1358894 is Effective in People With Depression

Phase 2

Terminated

Conditions: Depressive Disorder, Major

Interventions: Drug: BI 1358894
Drug: Placebo

First Posted Date: 2020-06-09

Last Posted Date: 2023-06-13

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 45

Registration Number: NCT04423757

Locations: 🇺🇸
Science 37, Inc., Culver City, California, United States

HORNBILL: A Study to Test Different Doses of BI 764524 in Patients Who Have Had Laser Treatment for a Type of Diabetic Eye Disease Called Diabetic Retinopathy With Diabetic Macular Ischemia

Phase 1

Completed

Conditions: Diabetic Retinopathy

Interventions: Drug: Sham control of BI 764524
Drug: BI 764524

First Posted Date: 2020-06-09

Last Posted Date: 2024-05-22

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 45

Registration Number: NCT04424290

Locations: 🇺🇸
Retina-Vitreous Associates Medical Group, Beverly Hills, California, United States
🇺🇸
Stanford University Medical Center, Palo Alto, California, United States
🇺🇸
New York Eye and Ear Infirmary of Mount Sinai, New York, New York, United States

and more 15 locations

A Study in Healthy Men to Compare 2 Different Formulations of Alteplase

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Alteplase (from current manufacturing process)
Drug: Alteplase (from modified manufacturing process)
Drug: Heparin-Natrium-5000-ratiopharm (unfractionated heparin)

First Posted Date: 2020-06-05

Last Posted Date: 2023-04-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 30

Registration Number: NCT04419493

Locations: 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany

A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

Phase 2

Completed

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: BI 1015550
Drug: Placebo

First Posted Date: 2020-06-05

Last Posted Date: 2022-11-01

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 147

Registration Number: NCT04419506

Locations: 🇨🇿
University Hospital Na Bulovce, Prague, Praha, Czechia
🇮🇹
Azienda Ospedaliera Universitaria di Padova, Padova, Italy
🇮🇹
A.O.U. Senese Policlinico Santa Maria alle Scotte, Siena, Italy

and more 72 locations

Tiotropium Plus Olodaterol vs Inhaled Corticosteroids (ICS) Regimens in the Portuguese Primary Care Setting (TIOLCOR Study)

Withdrawn

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: ICS
Drug: TIO/OLO

First Posted Date: 2020-05-27

Last Posted Date: 2021-11-05

Lead Sponsor: Boehringer Ingelheim

Registration Number: NCT04402515

A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis

Phase 2

Completed

Conditions: Generalized Pustular Psoriasis

Interventions: Drug: Placebo
Drug: Spesolimab

First Posted Date: 2020-05-22

Last Posted Date: 2023-12-14

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 123

Registration Number: NCT04399837

Locations: 🇩🇪
Universitätsklinikum Bonn AöR, Bonn, Germany
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇩🇪
Klinikum Oldenburg AöR, Oldenburg, Germany

and more 69 locations

A Trial in Healthy Chinese Volunteers to Test How Different Doses of BI 655130 Are Taken up in the Body

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Spesolimap

First Posted Date: 2020-05-15

Last Posted Date: 2023-08-07

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 50

Registration Number: NCT04390568

Locations: 🇨🇳
Huashan Hospital, Fudan University, Shanghai, China

A Study to Test How Different Doses of BI 456906 Are Tolerated in Japanese Men With a Body Mass Index (BMI) Between 23 and 40 kg/m2

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BI 456906
Drug: Placebo

First Posted Date: 2020-05-12

Last Posted Date: 2021-01-26

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 37

Registration Number: NCT04384081

Locations: 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku, Japan

A Study to Test Long-term Treatment With Spesolimab in Patients With Fistulising Crohn's Disease Who Took Part in Previous Trials

Phase 2

Terminated

Conditions: Crohn Disease

Interventions: Drug: Spesolimab

First Posted Date: 2020-04-24

Last Posted Date: 2025-02-24

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 12

Registration Number: NCT04362254

Locations: 🇧🇪
Centre Hospitalier Universitaire de Liège, Liège, Belgium
🇳🇱
Amsterdam UMC, Locatie AMC, Amsterdam, Netherlands
🇧🇪
UZ Leuven, Leuven, Belgium

and more 4 locations

Post-marketing Surveillance on Long Term Use of Ofev Capsules in Systemic Scleroderma Associated Interstitial Lung Disease (SSc-ILD) in Japan

Active, not recruiting

Conditions: Lung Diseases, Interstitial

Interventions: Drug: Nintedanib

First Posted Date: 2020-03-27

Last Posted Date: 2024-11-21

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 586

Registration Number: NCT04325217

Locations: 🇯🇵
Nippon Boehringer Ingelheim Co., Ltd., Tokyo, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy